While rates of deadly MRSA infections have plummeted dramatically in the United States, a closer look at the global data reveals a persistent and complex threat that demands our continued vigilance.
Key Takeaways
- In the United States, invasive MRSA infections decreased by 54% from 2005 to 2011, from 13.7 cases per 100,000 population to 6.6 cases per 100,000
- Globally, Staphylococcus aureus accounts for 20-30% of nosocomial bloodstream infections, with MRSA comprising 25-50% of those isolates
- In Europe, the ECDC reported a pooled MRSA prevalence of 17.1% among bloodstream S. aureus isolates in 2019
- Hospitalization for MRSA infections in US children increased 10-fold from 1999-2006
- Diabetes mellitus increases MRSA infection risk by 1.5-2.0 fold in meta-analyses
- Recent antibiotic use within 30 days raises MRSA isolation odds by 2.84 (95% CI 1.92-4.21)
- Skin infections present as abscesses in 70-80% of CA-MRSA cases
- MRSA bacteremia mortality rate is 20-50% depending on comorbidities
- Necrotizing fasciitis caused by MRSA has 25% amputation rate
- Vancomycin minimum inhibitory concentration (MIC) creep to 2 mg/L seen in 25% US MRSA isolates 2006-2012
- Daptomycin non-susceptibility develops in 10-20% of MRSA bacteremia treated with it
- Linezolid success rate 80% for MRSA skin infections, 70% for pneumonia
- Universal decolonization with chlorhexidine + mupirocin reduces MRSA cultures by 37%
- Hand hygiene compliance >70% halves MRSA transmission in ICUs
- Contact precautions reduce MRSA acquisition by 46% in endemic wards
The blog post highlights that MRSA infections have significantly declined in the United States.
Clinical Features
- Skin infections present as abscesses in 70-80% of CA-MRSA cases
- MRSA bacteremia mortality rate is 20-50% depending on comorbidities
- Necrotizing fasciitis caused by MRSA has 25% amputation rate
- In pneumonia, MRSA causes cavitary lesions in 30-50% of ventilator-associated cases
- Surgical site infections from MRSA occur in 1-2% of clean surgeries, deeper in contaminated ones up to 10%
- Osteomyelitis from MRSA requires surgery in 40-60% of pediatric cases
- Septic arthritis due to MRSA presents with fever in 85%, joint effusion in 95%
- MRSA endocarditis affects tricuspid valve in 25% of IVDU cases, aortic in 30%
- Toxic shock syndrome from MRSA has 5-15% mortality, multiorgan failure in 60%
- CA-MRSA strains produce Panton-Valentine leukocidin (PVL) in 80-100% of cases
- Median time to MRSA bacteremia positivity in blood cultures is 16-18 hours
- Purpura fulminans occurs in 5-10% of severe MRSA sepsis cases
- MRSA urinary tract infections are symptomatic in only 30%, often catheter-associated
- In neonates, MRSA conjunctivitis progresses to keratitis in 10-20% untreated
- Empyema complicates 5-15% of pediatric MRSA pneumonia cases
- Metastatic infections occur in 13-27% of MRSA bacteremia episodes
- Cellulitis from MRSA shows rapid spread, leukocytosis >15,000 in 70%
- Prosthetic joint infections by MRSA persist >6 weeks in 50% despite therapy
- Myocarditis reported in 1-2% of complicated MRSA bacteremia
- CA-MRSA furunculosis recurs in 10-20% within 3 months post-incision-drainage
- Splenic abscesses form in 2-5% of persistent MRSA bacteremias
- MRSA meningitis post-neurosurgery has 30% mortality
- Erythema nodosum-like lesions in 5% of disseminated CA-MRSA
- 30-day attributable mortality for MRSA bacteremia is 18% vs 11% MSSA
Clinical Features Interpretation
Mr. S. Aureus has refined its portfolio to offer a masterclass in opportunistic destruction, proving that whether it's a simple abscess or a fatal sepsis, it's always a serious contender that rarely misses an appointment.
Epidemiology
- In the United States, invasive MRSA infections decreased by 54% from 2005 to 2011, from 13.7 cases per 100,000 population to 6.6 cases per 100,000
- Globally, Staphylococcus aureus accounts for 20-30% of nosocomial bloodstream infections, with MRSA comprising 25-50% of those isolates
- In Europe, the ECDC reported a pooled MRSA prevalence of 17.1% among bloodstream S. aureus isolates in 2019
- In 2019, CDC estimated 119,247 S. aureus bloodstream infections in the US, of which 28% were MRSA
- Hospital-onset MRSA bacteremia incidence fell from 1.02 to 0.42 per 10,000 patient-days between 2005-2008 in US hospitals
- Community-associated MRSA accounted for 48.6% of invasive S. aureus infections in US children under 18 in 2012
- In Australia, MRSA bacteraemia notification rate was 36.1 per 100,000 population in 2018
- UK mandatory surveillance showed MRSA bacteraemia cases dropped 81.4% from 2001/02 to 2018/19, from 7,200 to 1,346 cases
- In China, MRSA prevalence among clinical S. aureus isolates reached 38.3% in a 2017 meta-analysis
- Latin America, MRSA rates in bloodstream infections averaged 42.7% from 1990-2010 per SENTRY study
- In US ICUs, MRSA colonization prevalence is 2-10% on admission, rising to 20% during stay
- Canadian Nosocomial Infection Surveillance Program reported MRSA bacteremia incidence of 5.1 per 10,000 patient-days in 2018
- In India, MRSA prevalence in hospitals was 34-62% in a 2020 systematic review
- Japan saw MRSA detection rates in hospitals drop from 70% in 1990s to 50% by 2016
- Africa, MRSA bloodstream prevalence estimated at 22% in 2019 review
- In US veterans, MRSA pneumonia incidence was 5.5 per 10,000 person-years in 2005-2010
- Netherlands achieved MRSA bacteremia rate of 0.47 per 10,000 patient-days via search-and-destroy policy
- In 2020, global MRSA burden estimated at 1.2 million deaths if trends continue
- US nursing homes report MRSA colonization in 20-30% of residents
- In South Korea, MRSA among S. aureus isolates was 69.2% in tertiary hospitals in 2018
- Italy's MRSA bacteraemia rate was 5.7 per 100,000 population in 2019
- Brazil SENTRY program showed 29.1% MRSA in bloodstream isolates 2013-2017
- In pediatric US populations, CA-MRSA skin infections rose 97% from 2004-2007
- Singapore reported MRSA bacteraemia incidence of 20.6 per 100,000 in 2015
- In France, MRSA frequency in bloodstream S. aureus fell to 13.1% in 2019
- Russia, MRSA prevalence in hospitals estimated at 15-20% in 2018 study
- US dialysis patients have MRSA bloodstream infection rate of 4.7 per 1,000 patient-months
- In New Zealand, MRSA notifications increased 5% annually 2010-2019
- Middle East MRSA bloodstream prevalence averaged 25% in 2015 meta-analysis
- In US prisons, MRSA colonization prevalence is 20-33% among inmates
Epidemiology Interpretation
We seem to be winning the battle in the hospital corridors but losing it in the schoolyards and streets, as MRSA cunningly retreats from one front only to fortify its position on another.
Prevention
- Universal decolonization with chlorhexidine + mupirocin reduces MRSA cultures by 37%
- Hand hygiene compliance >70% halves MRSA transmission in ICUs
- Contact precautions reduce MRSA acquisition by 46% in endemic wards
- Nasal mupirocin twice daily x5 days eradicates MRSA carriage in 85% short-term
- Daily chlorhexidine baths cut MRSA bloodstream infections by 23% in medical ICUs
- Active surveillance screening on admission detects 75% MRSA colonizers
- Antibiotic stewardship reduces MRSA incidence by 12% per DDD/1000 patient-days decrease
- Search-and-destroy policy in Netherlands keeps MRSA prevalence <1%
- Environmental cleaning with bleach wipes reduces surface MRSA by 90%
- Rapid PCR screening shortens isolation time, preventing 4.9 transmissions per 1000 screens
- Vaccination trials show anti-ClfA antibodies reduce MRSA skin infection in mice 70%
- Glove use with gowns increases compliance, cuts MRSA spread by 35%
- Decolonization protocols recur carriage prevention in 50% at 3 months
- UV-C disinfection of rooms post-discharge eliminates 91.7% MRSA bioburden
- Staff education programs boost hand hygiene to 85%, reduce HA-MRSA by 20%
- Targeted decolonization halves MRSA clinical cultures vs screening alone
- Copper surfaces reduce MRSA viability by 83% vs plastic after 2 hours
- Pre-surgical mupirocin prophylaxis cuts SSIs by 44% in S. aureus carriers
- No-touch automation in cleaning removes 99% MRSA from high-touch surfaces
- Visitor screening and masking in outbreaks prevents 25% secondary cases
- Hydrogen peroxide vapor decontamination achieves 99.99% MRSA log kill in rooms
- Community education on hygiene reduces CA-MRSA incidence by 15% in schools
- Device bundles (catheters) lower MRSA CRBSI to 0.5 per 1000 catheter-days
- Phage lysins lyse 99% MRSA cells in vitro within 2 hours
- Alcohol hand rubs more effective than soap, reduce MRSA transfer by 92%
Prevention Interpretation
The collective lesson from this data is that MRSA is a stubborn but decidedly defeatable foe whose spread can be dramatically curtailed through a relentless, multi-pronged attack combining obsessive hygiene, targeted decolonization, environmental vigilance, and prudent antibiotic use.
Risk Factors
- Hospitalization for MRSA infections in US children increased 10-fold from 1999-2006
- Diabetes mellitus increases MRSA infection risk by 1.5-2.0 fold in meta-analyses
- Recent antibiotic use within 30 days raises MRSA isolation odds by 2.84 (95% CI 1.92-4.21)
- Chronic kidney disease patients have 3.2 times higher MRSA bacteremia risk
- HIV infection associated with 2.6-fold increase in invasive MRSA disease
- Intravenous drug use elevates MRSA bloodstream infection risk by 4.7 (OR)
- Residence in long-term care facilities increases MRSA colonization risk by 3-5 times
- Prior hospitalization within 90 days triples MRSA infection probability
- Obesity (BMI >30) linked to 1.8-fold higher MRSA surgical site infection risk
- Immunosuppression from chemotherapy raises MRSA pneumonia odds by 2.1
- Close contact with healthcare workers colonized with MRSA increases acquisition risk 3.4-fold
- Nasal colonization with MRSA precedes 80-90% of subsequent infections
- Crowded living conditions in households boost CA-MRSA transmission risk by 2.5 OR
- Incarceration history associated with 2.9-fold CA-MRSA infection risk in civilians
- Peripheral vascular disease increases post-surgical MRSA risk by 2.2 times
- Children in daycare have 1.8 times higher CA-MRSA carriage rate
- Recent skin trauma or wounds elevate MRSA soft tissue infection risk 4.1-fold
- Liver cirrhosis patients face 3.5 higher MRSA bacteremia incidence
- Contact sports participation raises CA-MRSA skin infection risk by 3.0 OR
- Mechanical ventilation >48 hours increases ventilator-associated MRSA pneumonia by 5.2 OR
- Male gender associated with 1.4-fold higher MRSA colonization prevalence
- Age >65 years doubles invasive MRSA disease risk
- Residence in endemic communities increases CA-MRSA acquisition by 2.7 times
- Central venous catheter use linked to 4.0 OR for MRSA bacteremia
- African-American race/ethnicity shows 1.6-fold higher CA-MRSA infection rate
Risk Factors Interpretation
The MRSA data paints a sobering portrait of a modern plague that exploits our vulnerabilities, from hospital overstays and casual antibiotic scripts to crowded homes and chronic conditions, stitching a risk map where simply existing in the healthcare system or society at large can make you a target.
Treatment
- Vancomycin minimum inhibitory concentration (MIC) creep to 2 mg/L seen in 25% US MRSA isolates 2006-2012
- Daptomycin non-susceptibility develops in 10-20% of MRSA bacteremia treated with it
- Linezolid success rate 80% for MRSA skin infections, 70% for pneumonia
- Ceftaroline covers 95% of MRSA isolates with MIC90 1-2 mg/L
- Vancomycin trough target 15-20 mcg/mL reduces MRSA bacteremia failure by 50%
- Tedizolid has 4-fold potency over linezolid against MRSA, MIC90 0.25 mg/L
- Combination vancomycin + beta-lactam improves MRSA endocarditis cure rate to 70%
- Dalbavancin single-dose cures 93% complicated MRSA skin infections
- Oritavancin bactericidal against MRSA at 1 mg/L, non-susceptibility rare <1%
- Telavancin MIC90 for MRSA is 0.12 mg/L, nephrotoxicity 6% vs 1% vancomycin
- Clindamycin resistance in CA-MRSA 10-20%, inducible in 15% erythromycin-resistant
- Trimethoprim-sulfamethoxazole effective in 95% CA-MRSA skin infections
- Rifampin monotherapy fails in 20-30% due to rapid resistance emergence
- Fosfomycin MIC90 for MRSA 32-64 mg/L, synergy with beta-lactams in 80%
- Eravacycline active against MRSA MIC <=0.25 mg/L in 99% isolates
- Lefamulin inhibits MRSA at MIC90 2 mg/L, suitable for pneumonia
- Bacteriophage therapy clears MRSA in 80% chronic wound models
- Monoclonal antibody suvratoxumab prevents MRSA pneumonia in 35% ventilated patients
- Vancomycin area under curve (AUC)/MIC >400 predicts 90-day success in MRSA bacteremia
- Daptomycin dose 10 mg/kg/day achieves 70% success in vancomycin-failure MRSA
- Ceftaroline + daptomycin synergy in 92% MRSA isolates per checkerboard assay
- Quinupristin-dalfopristin success 65% in MRSA bacteremia, hepatotoxicity 5%
- Iclaprim topical 2% eradicates MRSA nasal carriage in 75% single application
- Omadacycline MIC90 0.5 mg/L for MRSA, oral bioavailability 30%
- Mupirocin resistance in MRSA nasal isolates rose to 10% in US hospitals 2010-2020
Treatment Interpretation
Our arsenal against MRSA is increasingly a game of tactical chess, where vancomycin's creeping mediocrity and daptomycin's betrayal push us toward a promising but costly array of new pieces, each with its own potent strength and lurking weakness.
Sources & References
- Reference 1CDCcdc.govVisit source
- Reference 2WHOwho.intVisit source
- Reference 3ECDCecdc.europa.euVisit source
- Reference 4JAMANETWORKjamanetwork.comVisit source
- Reference 5HEALTHhealth.gov.auVisit source
- Reference 6UKHSAukhsa.blog.gov.ukVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source
- Reference 9CANADAcanada.caVisit source
- Reference 10JMAJjmaj.jpVisit source
- Reference 11THELANCETthelancet.comVisit source
- Reference 12SANTEPUBLIQUEFRANCEsantepubliquefrance.frVisit source
- Reference 13HEALTHhealth.govt.nzVisit source
- Reference 14NEJMnejm.orgVisit source